FORMS RELATING TO LISTING

FORM F

The Growth Enterprise Market (GEM)

Company Information Sheet

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this information sheet, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name: CK Life Sciences Int'l., (Holdings) Inc.

Stock code (ordinary shares): 8222

This information sheet contains certain particulars concerning the above company (the "Company") which is listed on the Growth Enterprise Market ("GEM") of the Stock Exchange of Hong Kong Limited (the "Exchange"). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules"). They will be displayed at the GEM website on the Internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of 1st February, 2008.

Α. General

Place of incorporation	Cayman Islands	
Date of initial listing on GEM	: 16 July 2002	
Name of Sponsor(s)	: NA	
Names of directors: (please distinguish the status of the director - Executive, Non-Executive or Independent Non-Executive)	Executive Directors Li Tzar Kuoi, Victor Kam Hing Lam Ip Tak Chuen, Edmond Yu Ying Choi, Alan Abel Chu Kee Hung	
	<i>Non-Executive Director</i> Tulloch, Peter Peace	
	<i>Independent Non-Executive Directors</i> Wong Yue-chim, Richard Kwok, Eva Lee Russel, Colin Stevens	
Name(s) of substantial shareholder(s) (as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company	Name	Approximate percentage of holding
	Gold Rainbow Int'l Limited	44.30%
	Gotak Limited	44.30%
	Cheung Kong (Holdings) Limited	44.30%
	Li Ka-Shing Unity Trustee Company Limited as trustee of The Li Ka-Shing Unity Trust	44.30%

		Li Ka-Shing Unity Trustee Corporation Limited as trustee of The Li Ka-Shing Unity Discretionary Trust	44.30%
		Li Ka-Shing Unity Trustcorp Limited as trustee of another discretionary trust	44.30%
		Mr. Li Ka-shing	44.30%
		Trueway International Limited	22.05%
		Li Ka Shing Foundation Limited	29.50%
		Please also refer to the notes to the section headed "Interests and Short Positions of Shareholders" on pages 15 and 16 of the Third Quarter Report 2007 of the Company.	
Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company	:	Nil	
Financial year end date	:	31 December	
Registered address	:	P.O. Box 309GT, Ugland House, South Church Street, Grand Cayman, Cayman Islands	
Head office and principal place of business	:	 Head Office 2 Dai Fu Street, Tai Po Industrial Estate, Tai Po, Hong Kong 	
		Principal place of business 7th Floor, Cheung Kong Center, No.2, Queen's R Central, Hong Kong	Road
Web-site address (if applicable)	:	www.ck-lifesciences.com	
Share registrar		Cayman Islands principal share registrar Butterfield Fund Services (Cayman) Limited	
		Hong Kong branch share registrar Computershare Hong Kong Investor Services Limited	
Auditors	:	Deloitte Touche Tohmatsu	

B. Business activities

The Group is engaged in the research and development, manufacturing, commercialization, marketing and selling of environmental and human health products, as well as investment in various financial and investment products.

C. Ordinary shares

Number of ordinary shares in issue	:	9,611,072,400
Par value of ordinary shares in issue	:	HK\$0.10
Board lot size (in number of shares)	:	2,000
Name of other stock exchange(s) on which ordinary shares are also listed	:	Nil

D. Warrants

Stock code	:	NA
Board lot size	:	NA
Expiry date	:	NA
Exercise price	:	NA
Conversion ratio (Not applicable if the warrant is denominated in dollar value of conversion right)	:	NA
No. of warrants outstanding	:	NA
No. of shares falling to be issued upon the exercise or outstanding warrants	f :	NA
E. Other securities		
Number of share options granted and outstanding	:	14,146,101

Responsibility statement

The directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet ("the Information") and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

Signed:

Li Tzar Kuoi, Victor, by his lawful attorney, Kam Hing Lam	Chu Kee Hung, by his lawful attorney, Yu Ying Choi, Alan Abel	Russel Colin Stevens, by his lawful attorney, Yu Ying Choi, Alan Abel
Kam Hing Lam	Tulloch Peter Peace, by his lawful attorney, Yu Ying Choi, Alan Abel	
Ip Tak Chuen, Edmond	Wong Yue-chim, Richard, by his lawful attorney, Yu Ying Choi, Alan Abel	
Yu Ying Choi, Alan Abel	Kwok Eva Lee, by her lawful attorney, Yu Ying Choi, Alan Abel	